Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more
Pharma Reaserch Prod Co Ltd (214450) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.068x
Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) has a cash flow conversion efficiency ratio of 0.068x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩47.11 Billion) by net assets (₩688.78 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharma Reaserch Prod Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Pharma Reaserch Prod Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pharma Reaserch Prod Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharma Reaserch Prod Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Frontken Corporation Bhd
KLSE:0128
|
0.095x |
|
Zhejiang Chengchang Technology Co. Ltd.
SHE:001270
|
0.012x |
|
Gibraltar Industries Inc
NASDAQ:ROCK
|
0.077x |
|
CITIC Guoan Information Industry Co Ltd
SHE:000839
|
0.056x |
|
Construcciones y Auxiliar de Ferrocarriles S.A.
MC:CAF
|
0.141x |
|
Hebei Sinopack Electronic Technolog
SHE:003031
|
0.043x |
|
WILEY (JOHN) + SONS B
F:2F70
|
N/A |
|
IIFL Finance Limited
NSE:IIFL
|
-0.295x |
Annual Cash Flow Conversion Efficiency for Pharma Reaserch Prod Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Pharma Reaserch Prod Co Ltd from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩569.44 Billion | ₩139.88 Billion | 0.246x | +74.82% |
| 2023-12-31 | ₩462.19 Billion | ₩64.95 Billion | 0.141x | -18.75% |
| 2022-12-31 | ₩343.50 Billion | ₩59.40 Billion | 0.173x | -19.11% |
| 2021-12-31 | ₩305.44 Billion | ₩65.30 Billion | 0.214x | +61.97% |
| 2020-12-31 | ₩245.42 Billion | ₩32.39 Billion | 0.132x | +43.18% |
| 2019-12-31 | ₩209.07 Billion | ₩19.27 Billion | 0.092x | +250.09% |
| 2018-12-31 | ₩197.62 Billion | ₩5.20 Billion | 0.026x | -44.96% |
| 2017-12-31 | ₩178.85 Billion | ₩8.56 Billion | 0.048x | +0.60% |
| 2016-12-31 | ₩171.64 Billion | ₩8.16 Billion | 0.048x | -53.49% |
| 2015-12-31 | ₩156.75 Billion | ₩16.02 Billion | 0.102x | -- |